CTCX vs. LUCD, DXR, DRIO, NSPR, XAIR, CODX, LNSR, CTSO, APYX, and MODD
Should you be buying Carmell stock or one of its competitors? The main competitors of Carmell include Lucid Diagnostics (LUCD), Daxor (DXR), DarioHealth (DRIO), InspireMD (NSPR), Beyond Air (XAIR), Co-Diagnostics (CODX), LENSAR (LNSR), Cytosorbents (CTSO), Apyx Medical (APYX), and Modular Medical (MODD). These companies are all part of the "surgical & medical instruments" industry.
Carmell (NASDAQ:CTCX) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.
Carmell has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500.
Carmell has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -2,169.07%. Carmell's return on equity of -154.49% beat Lucid Diagnostics' return on equity.
In the previous week, Lucid Diagnostics had 4 more articles in the media than Carmell. MarketBeat recorded 7 mentions for Lucid Diagnostics and 3 mentions for Carmell. Carmell's average media sentiment score of 0.92 beat Lucid Diagnostics' score of 0.15 indicating that Carmell is being referred to more favorably in the media.
24.2% of Carmell shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 4.8% of Lucid Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Carmell has higher earnings, but lower revenue than Lucid Diagnostics.
Lucid Diagnostics has a consensus price target of $2.75, suggesting a potential upside of 196.34%. Given Lucid Diagnostics' higher probable upside, analysts plainly believe Lucid Diagnostics is more favorable than Carmell.
Lucid Diagnostics received 26 more outperform votes than Carmell when rated by MarketBeat users.
Summary
Lucid Diagnostics beats Carmell on 8 of the 13 factors compared between the two stocks.
Get Carmell News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTCX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
